Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

Study Summary

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.

Conditions

Relapsed or Refractory Lymphomas Advanced Solid Tumor

Interventions / Drugs

LP-284

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment110 participants

Primary Completion—

Lead SponsorLantern Pharma Inc.

Data Retrieved2026-04-11 04:20:13.316943+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.